Erratum to: What to Do, and What Not to Do, When Diagnosing and Treating Breakthrough Cancer Pain (BTcP): Expert Opinion

Erratum to: Drugs (2016) 76:315–330 DOI 10.1007/s40265-015-0519-2

Page 324, Table 1, which previously appeared as:

Table 1.

Characteristics of opioids used for BTP (times in minutes)

	Analgesic onset	Availability	Dwell time
Oral morphine	30–45′	30	NA
Oral oxycodone	30–45′	40–50	NA
OTFC	15–30	50	15
FBT	15	65	15
SLF	10–15	70	2
FBSF	15	65	2–5
INFS	5–10	80–90	NA
FPNS	5–10	70	NA

BTP breakthrough pain, FBT fentanyl buccal tablet, FBSF fentanyl buccal soluble film, FBNS fentanyl pectyn nasal spray, INFS intranasal fentanyl spray, OTFC oral transmucosal fentanyl cytrate, SLF sublingual fentanyl

Should appear as:

Table 1.

Characteristics of opioids used for BTP (times in minutes)

	Analgesic onset	Availability	Dwell time
Oral morphine	30–45′	30	NA
Oral oxycodone	30–45′	40–50	NA
OTFC	15–30	50	15
FBT	15	65	15
SLF	10–15	70	2
FBSF	15	65	2–5
INFS	5–10	80–90	NA
FPNS	5–10	70	NA
FCSL	6	~70	NA

BTP breakthrough pain, FBT fentanyl buccal tablet, FBSF fentanyl buccal soluble film, FBNS fentanyl pectin nasal spray, INFS intranasal fentanyl spray, OTFC oral transmucosal fentanyl citrate, SLF sublingual fentanyl, FCSL fentanyl citrate sublingual